Article
Janssen Biotech Inc. acquires license from Novo Nordisk for a development program focused on autoimmune diseases
Terms of the agreement have not been disclosed.
PRESS RELEASE
Bagsværd, Denmark, 20 May 2015 - Novo Nordisk A/S has signed an agreement with Janssen Biotech, Inc. (Janssen) under which Janssen will acquire an exclusive global licence to further develop and commercialise a clinical programme focused on therapy within autoimmune diseases. The programme targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor). Terms of the agreement have not been disclosed.
The agreement is subject to final clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Grants Full Approval to mRNA-1273 COVID-19 Vaccine in Children At Increased Risk
